CN102018721B - Chewable tablet of calcium carbonate dimeticone and preparation process - Google Patents
Chewable tablet of calcium carbonate dimeticone and preparation process Download PDFInfo
- Publication number
- CN102018721B CN102018721B CN2009102721884A CN200910272188A CN102018721B CN 102018721 B CN102018721 B CN 102018721B CN 2009102721884 A CN2009102721884 A CN 2009102721884A CN 200910272188 A CN200910272188 A CN 200910272188A CN 102018721 B CN102018721 B CN 102018721B
- Authority
- CN
- China
- Prior art keywords
- calcium carbonate
- dimeticone
- chewable tablet
- preparation
- simethicone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 title claims abstract description 25
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 title claims abstract description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 title claims abstract description 10
- 239000007910 chewable tablet Substances 0.000 title claims abstract description 6
- 229940068682 chewable tablet Drugs 0.000 title claims abstract description 6
- 229960001275 dimeticone Drugs 0.000 title claims abstract description 4
- CXQXSVUQTKDNFP-UHFFFAOYSA-N octamethyltrisiloxane Chemical compound C[Si](C)(C)O[Si](C)(C)O[Si](C)(C)C CXQXSVUQTKDNFP-UHFFFAOYSA-N 0.000 title claims abstract description 4
- 238000002360 preparation method Methods 0.000 title abstract description 7
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 9
- 235000019359 magnesium stearate Nutrition 0.000 claims abstract description 5
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 claims abstract description 4
- 108010011485 Aspartame Proteins 0.000 claims abstract description 3
- 229920002261 Corn starch Polymers 0.000 claims abstract description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims abstract description 3
- 239000000605 aspartame Substances 0.000 claims abstract description 3
- 235000010357 aspartame Nutrition 0.000 claims abstract description 3
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims abstract description 3
- 229960003438 aspartame Drugs 0.000 claims abstract description 3
- 239000008120 corn starch Substances 0.000 claims abstract description 3
- 235000010355 mannitol Nutrition 0.000 claims abstract description 3
- -1 siliciidoxydum Chemical compound 0.000 claims abstract description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229940008099 dimethicone Drugs 0.000 claims description 8
- 235000013870 dimethyl polysiloxane Nutrition 0.000 claims description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 claims description 8
- 229940069428 antacid Drugs 0.000 claims description 7
- 239000003159 antacid agent Substances 0.000 claims description 7
- 230000001458 anti-acid effect Effects 0.000 claims description 7
- 239000000741 silica gel Substances 0.000 claims description 5
- 229910002027 silica gel Inorganic materials 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 239000000796 flavoring agent Substances 0.000 claims description 2
- 235000019634 flavors Nutrition 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 abstract description 7
- 208000000718 duodenal ulcer Diseases 0.000 abstract description 4
- 208000008469 Peptic Ulcer Diseases 0.000 abstract description 3
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 abstract description 3
- 239000006260 foam Substances 0.000 abstract description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 3
- 229940083037 simethicone Drugs 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 208000024891 symptom Diseases 0.000 abstract description 2
- 206010020601 Hyperchlorhydria Diseases 0.000 abstract 1
- 206010051986 Pneumatosis Diseases 0.000 abstract 1
- 208000007107 Stomach Ulcer Diseases 0.000 abstract 1
- 201000005917 gastric ulcer Diseases 0.000 abstract 1
- 230000002045 lasting effect Effects 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
- 210000002784 stomach Anatomy 0.000 abstract 1
- 238000000034 method Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 239000008187 granular material Substances 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013530 defoamer Substances 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 2
- 206010016766 flatulence Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 208000011906 peptic ulcer disease Diseases 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 235000012239 silicon dioxide Nutrition 0.000 description 2
- 229940032120 simethicone 21 mg Drugs 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000005065 mining Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000012056 semi-solid material Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229940035288 titralac Drugs 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention discloses a chewable tablet of calcium carbonate dimeticone and a preparation process, belonging to four new national chemical medicines. The preparation of the invention is prepared from the following main components: calcium carbonate, simethicone, siliciidoxydum, aspartame, essence powder, mannite, corn starch, low-substituted hydroxypropyl cellulose and magnesium stearate, wherein the calcium carbonate as the main content has stronger acid-resisting action and rapid and lasting effects, and the simethicone is a foam suppressor for eliminating gastrointestinal tract pneumatosis. The preparation is used for treating peptic ulcers including stomach and duodenal ulcer and easing various uncomfortable symptoms caused by hyperacidity.
Description
Technical field
The invention belongs to traditional Chinese medicines chemical drugs four kind new medicines.
Background technology
Peptic ulcer comprises gastric duodenal ulcer, is a kind of time-honored commonly encountered diseases, the sickness rate average out to 8-10% in the crowd.The reasonability of antacid and medication inexpensive because of it, and meet current national Health care system, be a kind of main medicine of treatment peptic ulcer.Antacid is generally alkaline compound, thus in vivo can in remove its stimulation and damage with gastric acid to the gastric duodenal ulcer face, can relief of symptoms, help the reparation of ulcer.Clinically compound recipes that adopt antacid and other drug to form, defoamer is a kind of for wherein more.Defoamer can be eliminated the foam in the gastrointestinal tract because surface tension is little, and the gas of being stored by foam is released, and alleviates flatulence, and the gastrointestinal tract flatulence that a variety of causes is caused has positive effect.This product is the compound preparation of antacid calcium carbonate and defoamer dimethicone.
Summary of the invention
The present invention has mainly provided prescription and the method for preparing that a kind of new antacid class is treated the chemical drugs of gastric duodenal ulcer, and said preparation prescription and method for preparing are domestic to be used as yet.
Prescription of the present invention is: calcium carbonate 420.0g; Dimethicone 20.0g; Micropowder silica gel 1.0g; Aspartame 3.0g; Powdered flavor 3.0g; Mannitol 200.0g; Corn starch 13.5g; Low-substituted hydroxypropyl cellulose 15.0g; Magnesium stearate 4.0g.
Method for preparing of the present invention is: formula ratio is pressed with dimethicone, micropowder silica gel mix homogeneously in (1), adds the calcium carbonate of crossing 120 mesh sieves again and fully mixes, and it is subsequent use to cross 40 mesh sieves.(2) other adjuvants of having crossed mesh sieve except that magnesium stearate are added in (1), cross 80 mesh sieve mix homogeneously.(3) add 5% starch slurry and process soft material, cross 16 orders and granulate.(4) put in 50 ℃ of baking ovens and dry.Press formula ratio in the granule and add magnesium stearate, cross 20 order granulate.Survey in the granule behind the drug content tabletting.
The specific embodiment
With reference to the Titralac of Minnesota Mining and Manufacturing Company
TMThe dosage formulation of plus Antacid chewable tablet is formed: every carbonated calcium 420mg, Simethicone 21mg, the wherein mixture of Simethicone dimethicone and silicon dioxide.Dimethicone is an active substance; The micropowder silica gel main component is a silicon dioxide, and to increase the distribution area of dimethicone, content is 4～7% as dispersant.Adopt external report method with 20mg dimethicone and 1mg micropowder silica gel mix homogeneously in this research, its semi-solid material is equivalent to Simethicone 21mg.
In the prescription screening process, because 3M company's T itralac
TMPlus Antacid chewable tablet both can be chewed, and can swallow again, so be index with mouthfeel, outward appearance and the disintegrate etc. of tablet mainly, investigated disintegrate emphatically, through selecting different auxiliary materials and consumption for use, confirmed more reasonably prescription.
Concrete screening process sees the following form.
Table 1: prescription screening
Annotate: L-HPC is that low-substituted hydroxypropyl cellulose, CMS-Na are for completing methyl starch sodium
Through prescription screening, the 4 gained tablet mouthfeels of filling a prescription.Outward appearance and disintegrate are all better.So select for use this prescription as end formulation.
Claims (1)
1. a calcium carbonate dimeticone chewable tablet is characterized in that, and is formulated by following material: antacid calcium carbonate 420.0g; Froth breaking medicine dimethicone 20.0g; Micropowder silica gel 1.0g; Aspartame 3.0g; Powdered flavor 3.0g; Mannitol 200.0g; Corn starch 13.5g; Low-substituted hydroxypropyl cellulose 15.0g; Magnesium stearate 4.0g.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2009102721884A CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102018721A CN102018721A (en) | 2011-04-20 |
| CN102018721B true CN102018721B (en) | 2012-08-22 |
Family
ID=43860771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2009102721884A Expired - Fee Related CN102018721B (en) | 2009-09-23 | 2009-09-23 | Chewable tablet of calcium carbonate dimeticone and preparation process |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102018721B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104523717A (en) * | 2015-01-06 | 2015-04-22 | 西南大学 | Simethicone otilonium bromide chewable tablets and preparing method thereof |
| CN106860475A (en) * | 2017-02-17 | 2017-06-20 | 北京沃邦医药科技有限公司 | A kind of preparation method of calcium carbonate D3 tablets |
| WO2022060310A1 (en) * | 2020-09-18 | 2022-03-24 | Pharmacti̇ve İlaç Sanayi̇ Ve Ti̇caret A.Ş. | Pharmaceutical compositions comprising calcium carbonate, magnesium carbonat and simethicone |
| DK202330347A1 (en) * | 2023-11-25 | 2025-06-12 | Fertin Pharma As | Coated soft chew tablets suitable for antacids |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170358A (en) * | 1994-12-16 | 1998-01-14 | 沃特森实验室公司 | Chewable dosage forms |
-
2009
- 2009-09-23 CN CN2009102721884A patent/CN102018721B/en not_active Expired - Fee Related
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1170358A (en) * | 1994-12-16 | 1998-01-14 | 沃特森实验室公司 | Chewable dosage forms |
Non-Patent Citations (3)
| Title |
|---|
| 徐凌云等.复方二甲基硅油咀嚼片治疗急性消化系统症状的临床研究.《中国临床药理学与治疗学》.2005,第10卷(第1期), * |
| 徐可树等.复方二甲基硅油对功能性肠胀气的疗效观察.《世界华人消化杂志》.2004,第12卷(第7期), * |
| 施昕磊等.咀嚼片的研究进展.《中国药业》.2008,第17卷(第14期), * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102018721A (en) | 2011-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RO118563B1 (en) | Dosed oral composition with instantaneous decomposition, and process for obtaining the same | |
| MXPA04000223A (en) | Novel substituted benzimidazole dosage forms and method of using same. | |
| JP2009292843A (en) | Solid pharmaceutical preparation | |
| CN1225017A (en) | Quickly disintegrable compression-molded materials and process for producing the same | |
| CN102018721B (en) | Chewable tablet of calcium carbonate dimeticone and preparation process | |
| EP2389070B1 (en) | Disintegrable formulations of lanthanum carbonate | |
| JP2001513801A (en) | Swallow tablets containing paracetamol | |
| CN103656654A (en) | Instant orally-disintegrating tablet and its preparation method | |
| JP4939680B2 (en) | Solid preparation | |
| CN103301467A (en) | Stable taste-masking ambroxol hydrochloride compound and preparation method thereof | |
| CN102512402B (en) | Novel preparation of medicine for treating gastric and duodenal ulcers and preparation method thereof | |
| WO2000035418A2 (en) | Chewable drug delivery system | |
| JP2017119655A (en) | Orally disintegrating tablet containing lanthanum carbonate | |
| CN101401796A (en) | Pramipexole orally disintegrating tablets and preparation method thereof | |
| CN101461832A (en) | Bioadhesive paster for treating mouth ulcer | |
| CN100471497C (en) | Naloxone Hydrochloride nose powder preparation | |
| CN101269055B (en) | Ambroxol hydrochloride oral cavity disintegrating tablet and method of producing the same | |
| CN103877036A (en) | Rapid disintegrant preparation composition of bismuth subsalicylate and preparing method thereof | |
| CN102872024A (en) | Misoprostol medicine combination used in mouths | |
| CN101099747A (en) | Compound alginic acid chewing tablet and preparation method thereof | |
| CN101574320A (en) | Intestinal protection medicament and preparation method thereof | |
| CN115737582B (en) | A kind of aluminum carbonate chewable tablet and preparation method thereof | |
| CN103432596B (en) | Method for researching abirritation mechanism of Chinese herbal medicinal ingredients of Xinhuang tablets | |
| CN102488708B (en) | Magaldrate chewable tablets and preparation method thereof | |
| PT836472E (en) | EFFERVESCENT THERAPEUTIC COMPOSITIONS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200810 Address after: 430000 Guannan science and Technology Industrial Park, Donghu Development Zone, Wuhan City, Hubei Province Patentee after: Hubei Huquan Pharmaceutical Co.,Ltd. Address before: 430073, No. 81 Nanhu Avenue, Guan Nan Industrial Park, East Lake New Technology Development Zone, Hubei, Wuhan Patentee before: HUANGSHI LISHIZHEN PHARMACEUTICAL GROUP WUHAN LISHIZHEN PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120822 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |